Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?

Trial Profile

Among ICSI Patients Undergoing Antagonist Protocols With Recombinant FSH, Does Replacement of Recombinant FSH by 200 IU of hCG in the Late Follicular Phase Compared With Continuing Recombinant FSH, Result in a Similar Number of Oocytes?

Completed
Phase of Trial: Phase IV

Latest Information Update: 08 Oct 2010

At a glance

  • Drugs Chorionic gonadotropin (Primary) ; Follitropin beta (Primary) ; Ganirelix (Primary) ; Progesterone
  • Indications Infertility
  • Focus Therapeutic Use
  • Most Recent Events

    • 08 Oct 2010 Planned end date added to 1 Nov 2008 as reported by ClinicalTrials.gov.
    • 08 Oct 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 01 Nov 2009 Results reported in Human Reproduction.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top